

# Michael D Devous

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5684034/publications.pdf>

Version: 2024-02-01

80  
papers

4,751  
citations

147801

31  
h-index

133252

59  
g-index

93  
all docs

93  
docs citations

93  
times ranked

5516  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.8	603
2	Regional profiles of the candidate tau PET ligand <sup>18</sup> F-AV-1451 recapitulate key features of Braak histopathological stages. <i>Brain</i> , 2016, 139, 1539-1550.	7.6	372
3	Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 871-881.	30.7	354
4	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 2612.	12.8	283
5	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. <i>Brain</i> , 2017, 140, aww334.	7.6	257
6	Positron Emission Tomography Imaging With [ <sup>18</sup> F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <i>JAMA Neurology</i> , 2020, 77, 829.	9.0	244
7	Risk Factors for $\beta$ -Amyloid Deposition in Healthy Aging. <i>JAMA Neurology</i> , 2013, 70, 600.	9.0	216
8	Tau Positron-Emission Tomography in Former National Football League Players. <i>New England Journal of Medicine</i> , 2019, 380, 1716-1725.	27.0	165
9	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. <i>Brain</i> , 2019, 142, 1723-1735.	7.6	156
10	<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017, 82, 622-634.	5.3	148
11	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 4.	6.2	134
12	Distinctive disruption patterns of white matter tracts in Alzheimer's disease with full diffusion tensor characterization. <i>Neurobiology of Aging</i> , 2012, 33, 2029-2045.	3.1	104
13	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. <i>Alzheimer's and Dementia</i> , 2018, 14, 1565-1571.	0.8	98
14	Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 373-379.	2.6	90
15	Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults. <i>JAMA Neurology</i> , 2017, 74, 830.	9.0	87
16	Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. <i>NeuroImage</i> , 2012, 62, 1-8.	4.2	84
17	Kinetics of the Tau PET Tracer <sup>18</sup> F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1535-1542.	5.0	84
18	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 412-419.	2.4	80

#	ARTICLE	IF	CITATIONS
19	Risk factors for mild cognitive impairment among Mexican Americans. <i>Alzheimer's and Dementia</i> , 2013, 9, 622.	0.8	79
20	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. <i>Journal of Nuclear Medicine</i> , 2018, 59, 944-951.	5.0	73
21	Biomarkers of Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 841-849.	2.6	69
22	Cortico-Amygdala Coupling as a Marker of Early Relapse Risk in Cocaine-Addicted Individuals. <i>Frontiers in Psychiatry</i> , 2014, 5, 16.	2.6	63
23	Dopamine efflux in response to ultraviolet radiation in addicted sunbed users. <i>Psychiatry Research - Neuroimaging</i> , 2016, 251, 7-14.	1.8	62
24	A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1736-1741.	5.0	61
25	Testâ€Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. <i>Journal of Nuclear Medicine</i> , 2018, 59, 937-943.	5.0	55
26	Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1351-1364.	2.6	48
27	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. <i>JAMA Psychiatry</i> , 2022, 79, 464.	11.0	47
28	The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 701-706.	2.6	45
29	Quantification of Tau Load Using [18F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	2.6	42
30	Topographic staging of tau positron emission tomography images. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 221-231.	2.4	41
31	Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 825-837.	6.4	40
32	Effectiveness of Florbetapir PET Imaging in Changing Patient Management. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 129-143.	1.5	35
33	Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach. <i>BMC Bioinformatics</i> , 2016, 17, 357.	2.6	34
34	Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. <i>Alzheimer's and Dementia</i> , 2017, 13, 1117-1124.	0.8	31
35	Amyloid deposition in younger adults is linked to episodic memory performance. <i>Neurology</i> , 2016, 87, 2562-2566.	1.1	27
36	Technical Considerations in Brain Amyloid PET Imaging with <sup>18</sup> F-Florbetapir. <i>Journal of Nuclear Medicine Technology</i> , 2015, 43, 175-184.	0.8	26

#	ARTICLE	IF	CITATIONS
37	Comparison of relative cerebral blood flow maps using pseudo-continuous arterial spin labeling and single photon emission computed tomography. <i>NMR in Biomedicine</i> , 2012, 25, 779-786.	2.8	25
38	The effect of beta-amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal. <i>Human Brain Mapping</i> , 2015, 36, 2514-2526.	3.6	25
39	Quantification of 18F-florbetapir PET: comparison of two analysis methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 725-732.	6.4	25
40	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. <i>EJNMMI Research</i> , 2020, 10, 65.	2.5	25
41	Altered Neural Processing of Threat in Alcohol-Dependent Men. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 2029-2038.	2.4	23
42	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1037-1048.	2.6	22
43	Parametric methods for [ <sup>18</sup> F]flortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 365-373.	4.3	22
44	A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 163-170.	2.6	21
45	0806: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR 18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A 2-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER'S DISEASE (AD). <i>Alzheimer's and Dementia</i> , 2016, 12, P352.	0.8	19
46	Striatal limbic activation is associated with intensity of anticipatory anxiety. <i>Psychiatry Research - Neuroimaging</i> , 2012, 204, 123-131.	1.8	17
47	Interaction between early life stress and alcohol dependence on neural stress reactivity. <i>Addiction Biology</i> , 2015, 20, 523-533.	2.6	17
48	Caudolateral orbitofrontal regional cerebral blood flow is decreased in abstinent cocaine-addicted subjects in two separate cohorts. <i>Addiction Biology</i> , 2012, 17, 1001-1012.	2.6	11
49	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	12.8	11
50	P4-316: MEASURING CHANGE IN BETA-AMYLOID BURDEN OVER TIME USING FLORBETAPIR-PET AND A SUBCORTICAL WHITE MATTER REFERENCE REGION. , 2014, 10, P902-P902.		8
51	ICP022: Conversion of Amyloid Quantitation With Florbetapir Suvr to The Centiloid Scale. <i>Alzheimer's and Dementia</i> , 2016, 12, P25.	0.8	6
52	Differences in regional cerebral blood flow response to a 5HT3 antagonist in early- and late-onset cocaine-dependent subjects. <i>Addiction Biology</i> , 2014, 19, 250-261.	2.6	5
53	ICP183: EMPLOYING EARLY UPTAKE DATA FROM F18-FLORBETAPIR SCANS AS AN ESTIMATE OF REGIONAL CEREBRAL BLOOD FLOW: COMPARISON TO F18-FDG. <i>Alzheimer's and Dementia</i> , 2014, 10, P102.	0.8	5
54	IC-O3-01: The Centiloid Scale: Standardization of amyloid imaging measures. , 2013, 9, P8-P8.		4

#	ARTICLE	IF	CITATIONS
55	123I-iodofluorane Single-Photon Emission Computed Tomography as an Imaging Biomarker of Pre-Synaptic Dopaminergic System after Moderate-to-Severe Traumatic Brain Injury. Journal of Neurotrauma, 2020, 37, 2113-2119.	3.4	4
56	DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18) Tj ETQq0 0 0 rgBT /Overglock 10 Tf		
57	[O5â€“01â€“01]: PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD. Alzheimer's and Dementia, 2017, 13, P1452.	0.8	3
58	P4-314: TEST-RETEST DATA FOR THE TAU PET IMAGING AGENT 18F-AV-1451 (PREVIOUSLY, 18F-T807). , 2014, 10, P901-P901.		2
59	O1â€“07â€“06: Hippocampal sparing and limbic predominant tau subtypes of Alzheimer's disease determined <i>in vivo</i> using [18F]â€“AVâ€“1451 PET imaging. Alzheimer's and Dementia, 2015, 11, P144.	0.8	2
60	O1-07-05: IMPACT OF B-AMYLOID BURDEN ON BRAIN PERFUSION AND VASCULAR REACTIVITY IN NORMAL AGING. , 2014, 10, P143-P144.		1
61	IC-P-171: Region-dependent kinetics of the Tau PET tracer [18 F]-AV-1451 (T807). , 2015, 11, P113-P113.		1
62	[P2â€“383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY: A PILOT CLINICOâ€“PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P776.	0.8	1
63	DTâ€“01â€“05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSYâ€“VALIDATED CASES. Alzheimer's and Dementia, 2019, 15, P1486.	0.8	1
64	P4-136: DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR-PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE?. , 2014, 10, P836-P837.		0
65	P4-311: IS FLORBETAPIR-PET OCCIPITAL SUVR A LATE BIOMARKER IN MILD OR MODERATE AD DEMENTIA AS COMPARED TO HIPPOCAMPAL VOLUME?. , 2014, 10, P900-P900.		0
66	IC-01-02: AMYLOID ACCUMULATION IN EARLY AND MIDDLE ADULTHOOD: THE IMPACT OF LIFE EXPERIENCE. , 2014, 10, P1-P1.		0
67	P4-306: EFFECTS OF IN VIVO AMYLOID BURDEN ON COGNITION IN HEALTHY ADULTS AGED 30 TO 89: INITIAL LONGITUDINAL RESULTS ACROSS 3.5 YEARS FROM THE DALLAS LIFESPAN BRAIN STUDY. , 2014, 10, P897-P898.		0
68	IC-P-030: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials. , 2015, 11, P29-P30.		0
69	P4-259: Relationships between cognitive assessments and spatial distribution of neuropathological tau as assessed by 18 F AV-1451 PET scanning. , 2015, 11, P881-P881.		0
70	IC-P-165: Understanding the topology of 18 F-AV-1451 (also known as T807) PET tau images in Alzheimer's disease. , 2015, 11, P110-P111.		0
71	ICâ€“Pâ€“196: Quantification of TAU Load Using [ <sup>18</sup> F]AVâ€“1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
72	O4â€“02â€“05: The Relationship of [18F]AVâ€“1451 Pet Tau Images to Changes in Cognition Over Time. Alzheimer's and Dementia, 2016, 12, P336.	0.8	0

#	ARTICLE	IF	CITATIONS
73	IC-P-134: Differentiating Preclinical Alzheimer's Disease from Normal Aging: The Effects of Age and Amyloid on Cognitive Decline Over 3.5 Years. , 2016, 12, P100-P100.		0
74	O1-07-02: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]AV-1451 (T807) PET Studies. Alzheimer's and Dementia, 2016, 12, P189.	0.8	0
75	O4-07-01: Evolution of [18 F]Av-1451 Pet Tau Signal: Interim Analysis of an 18-Month Phase 2 Study. , 2016, 12, P347-P347.		0
76	[IC-01-04]: A ROBUST, SIMPLIFIED BRAAK-TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR F-18 TAU PET IMAGES. Alzheimer's and Dementia, 2017, 13, P3.	0.8	0
77	[P4-227]: THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS. Alzheimer's and Dementia, 2017, 13, P1357.	0.8	0
78	[P4-235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.8	0
79	[P4-530]: MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE SPECTRUM USING [18F]FLORTAUCIPIR PET IMAGING. Alzheimer's and Dementia, 2017, 13, P1552.	0.8	0
80	IC-P-216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL. Alzheimer's and Dementia, 2018, 14, P177.	0.8	0